<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pediatric HIV infection: Classification, clinical manifestations, and outcome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pediatric HIV infection: Classification, clinical manifestations, and outcome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pediatric HIV infection: Classification, clinical manifestations, and outcome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan L Gillespie, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mary E Paul, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H18840477"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Considerable progress has been made towards eliminating HIV among children; however, the global burden of pediatric HIV and acquired immune deficiency syndrome (AIDS) remains a challenge for health care workers around the world, particularly in resource-limited settings [<a href="#rid1">1</a>].</p><p>The case definition and classification of pediatric HIV infection, clinical manifestations of some of the AIDS-defining conditions  (<a class="graphic graphic_table graphicRef59724" href="/d/graphic/59724.html" rel="external">table 1</a>), and outcomes of HIV infection in children are reviewed here. The epidemiology of pediatric HIV, prophylactic treatment of infants born to mothers with HIV, diagnostic testing for HIV in young children, approach to febrile HIV-infected infants and children, and issues related to HIV infection in adolescents are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5962.html" rel="external">"Epidemiology of pediatric HIV infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/126417.html" rel="external">"Intrapartum and postpartum management of pregnant women with HIV and infant prophylaxis in resource-rich settings", section on 'Infant prophylaxis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6006.html" rel="external">"Diagnostic testing for HIV infection in infants and children younger than 18 months"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6007.html" rel="external">"The adolescent with HIV infection"</a>.)</p><p></p><p>The details of antiretroviral therapy (ART) for pediatric HIV infection are beyond the scope of these topic reviews. <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines%2Fpediatric-arv%2Fwhats-new-guidelines&amp;token=pEc0khDLuBYA0kQ3VswYr0Rm%2BbLkaXoie410LYjRFnHbzZ5jc7EDJNsUDoCPwOILg%2F3ulVcx3YnT3OUtsLVqKG%2B%2B17G2NMDSePQpb19VfBc%3D&amp;TOPIC_ID=5963" target="_blank">Guidelines</a> on the treatment of pediatric HIV infection are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=5963" target="_blank">HIV.gov Clinical Info website</a>.</p><p class="headingAnchor" id="H18840484"><span class="h1">CASE DEFINITIONS</span><span class="headingEndMark"> — </span>The Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) each have established case definitions for HIV infection and acquired immune deficiency syndrome (AIDS) in children and adults to standardize the description of HIV infection cases for public health surveillance and research purposes. These classification systems are useful for characterizing HIV infection in the United States (CDC) and in the developing world (WHO) and are described briefly below.</p><p class="headingAnchor" id="H18840491"><span class="h2">Centers for Disease Control and Prevention classification system</span><span class="headingEndMark"> — </span>In 2014, the CDC revised the surveillance case definition for HIV infection to incorporate diagnostic testing algorithms that do not rely on Western blot or immunofluorescence HIV antibodies  (<a class="graphic graphic_table graphicRef95236" href="/d/graphic/95236.html" rel="external">table 2</a>) [<a href="#rid2">2</a>]. The 2014 surveillance case definition applies to persons of all ages; the previous version had separate case definitions for adults and adolescents ≥13 years and children younger than 13 years [<a href="#rid3">3</a>]. The CDC surveillance case definitions are used primarily for monitoring the HIV infection burden and planning for prevention and care in populations, <strong>not</strong> as the basis for clinical decisions in individual patients.</p><p>The 2014 revised case definition classifies HIV infection in all age groups as stage 1, 2, or 3 based upon the absolute CD4 count  (<a class="graphic graphic_table graphicRef95235" href="/d/graphic/95235.html" rel="external">table 3</a>), unless the individual has had a stage 3 (ie, AIDS-defining) opportunistic illness  (<a class="graphic graphic_table graphicRef59724" href="/d/graphic/59724.html" rel="external">table 1</a>). The CD4 percentage is used only when the corresponding CD4 count is unknown, even for young children. Specific criteria are provided for different age groups (&lt;1 year, 1 through 5 years, and ≥6 years). If no CD4 count or percentage is known, the stage is classified as unknown. If a stage 3 opportunistic illness has been diagnosed, then the stage is 3 regardless of the CD4 absolute count or percentage. The CDC staging system indicates the most severe stage in the individual's lifetime and does not provide for assigning a revised, less severe stage after antiretroviral therapy (ART)-mediated improvement in HIV-related symptom severity.</p><p>Stage 0 indicates early HIV infection and allows routine monitoring of cases diagnosed within several months after infection. Stage 0 includes the most highly infectious period when viral loads are extremely high and intervention may be most effective in preventing secondary transmission of infection to others. The criteria for stage 0 supersede and are independent of the criteria used for other stages.</p><p class="headingAnchor" id="H18840498"><span class="h2">World Health Organization classification system</span><span class="headingEndMark"> — </span>The WHO classification system for pediatric HIV/AIDS [<a href="#rid4">4</a>] uses clinical or immunologic criteria for patients with laboratory-confirmed HIV infection  (<a class="graphic graphic_table graphicRef104882" href="/d/graphic/104882.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef57988" href="/d/graphic/57988.html" rel="external">table 5</a>).</p><p>This four-stage system (ie, WHO clinical stage 1 to WHO clinical stage 4) classifies an individual's clinical status from asymptomatic to severely symptomatic. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fapps.who.int%2Firis%2Fhandle%2F10665%2F43699&amp;token=jOlj5rfph3GjqGB8X0FCvBsND5uleaHDdx5Qogfy9vNd7HFkqWa2jRF9Z1q831JRHI76f3JWLa9XFnez%2FsuQkA%3D%3D&amp;TOPIC_ID=5963" target="_blank">WHO classification</a> also includes criteria for the presumptive diagnosis of advanced HIV infection in HIV-exposed infants based on clinical criteria, allowing practitioners in resource-limited areas to initiate lifesaving ART before definitive laboratory diagnosis is completed.</p><p>To track improvement or worsening, staging continues after commencing ART using the same clinical criteria  (<a class="graphic graphic_table graphicRef104882" href="/d/graphic/104882.html" rel="external">table 4</a>) and denoting the stage as "T1," "T2," "T3," or "T4" to indicate that the assessment was made on ART.</p><p>The WHO recommends initiating ART for all infants, children, and adolescents living with HIV, regardless of WHO clinical stage and/or CD4 count [<a href="#rid5">5</a>]. Children with HIV in the following categories are considered to be at the highest priority for initiating ART:</p><p class="bulletIndent1"><span class="glyph">●</span>WHO stage 3 or 4</p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;2 years</p><p class="bulletIndent1"><span class="glyph">●</span>Age 2 to 5 years with CD4 count ≤750 cells/mm<sup>3 </sup>or CD4 percentage &lt;25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥5 years with CD4 count ≤350 cells/mm<sup>3</sup></p><p></p><p class="headingAnchor" id="H18840505"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Clinical manifestations of HIV infection in infants and children are varied and often nonspecific. Lymphadenopathy, frequently in association with hepatosplenomegaly, can be an early sign of infection. During the first year of life, oral candidiasis, pneumonia, failure to thrive, and developmental delay are common presenting features of HIV infection. As HIV infection persists without effective treatment, children experience progressive immunosuppression and develop acquired immune deficiency syndrome (AIDS). The most common AIDS-defining conditions observed among American children with vertically acquired HIV infection include:</p><p class="bulletIndent1"><span class="glyph">●</span><em>Pneumocystis</em> <em>jirovecii</em> pneumonia (PCP)</p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal candidiasis</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent bacterial infections</p><p class="bulletIndent1"><span class="glyph">●</span>Wasting syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Cytomegalovirus (CMV) pneumonia, colitis, encephalitis, or retinitis </p><p class="bulletIndent1"><span class="glyph">●</span>HIV encephalopathy</p><p></p><p><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines%2Fpediatric-opportunistic-infection%2Fwhats-new&amp;token=X216ZCNvyHZSg1WjlZhGK4ec4aZTbO7BnYnsGqNl3Qtjt6bIiMXrwOYg5TFr2M3ZwNeOsKM7C8V4btCotBW1wM1dHTHb%2Bhc6j%2BDFZN7C7WM%3D&amp;TOPIC_ID=5963" target="_blank">Guidelines</a> for the prevention and treatment of opportunistic infections (OIs) in children with HIV are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=5963" target="_blank">HIV.gov Clinical Info website</a>.</p><p class="headingAnchor" id="H334974148"><span class="h2">Effect of combination antiretroviral therapy</span><span class="headingEndMark"> — </span>The use of highly effective combination antiretroviral therapy (ART) has led to a decline in the incidence of OI in children with vertically acquired HIV infection [<a href="#rid6">6-9</a>]. In a study that evaluated data from 364 children with HIV born from 1986 to 1998 and monitored until 2004, the overall incidence rate of OI decreased from 14.4 cases per 100 person-years before 1997 (ie, prior to use of combination ART) to 1.1 cases per 100 person-years after 1997 [<a href="#rid7">7</a>]. The incidence rates of specific infections before and after combination ART were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>PCP (5.8 versus 0.3 cases per 100 person-years)</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent bacterial infection (4.7 versus 0.2 cases per 100 person-years)</p><p class="bulletIndent1"><span class="glyph">●</span>Extraocular CMV (1.4 versus 0.1 cases per 100 person-years)</p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated nontuberculous mycobacterium (1.3 versus 0.2 cases per 100 person-years)</p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal candidiasis (0.9 versus 0.4 cases per 100 person-years)</p><p class="bulletIndent1"><span class="glyph">●</span>Herpes simplex virus (0.2 versus 0 cases per 100 person-years)</p><p></p><p class="headingAnchor" id="H11141044"><span class="h2">Selected AIDS-defining conditions</span></p><p class="headingAnchor" id="H18840512"><span class="h3">Pneumocystis jirovecii pneumonia</span><span class="headingEndMark"> — </span>PCP accounts for approximately one-half of all AIDS-defining conditions diagnosed during the first year of life. The median age at diagnosis of PCP in children in one series was five months [<a href="#rid10">10</a>]. In adults and older children, PCP develops in individuals with CD4 counts &lt;200 cells/microL or CD4 percent &lt;15 as well as in patients with poor virologic control. In infants, however, PCP can develop with CD4 counts &gt;200 cells/microL.</p><p>PCP should be suspected in patients with low-grade fever, tachypnea, nonproductive cough, and progressive shortness of breath. The onset of symptoms may be insidious, with nonspecific symptoms of mild cough, dyspnea, poor feeding, diarrhea, and weight loss. On physical examination, lung auscultation may be normal even in the presence of severe clinical disease and hypoxemia; rales and rhonchi may not become apparent until late in the clinical course. In children with HIV and PCP, four clinical variables are independently associated with PCP: age &lt;6 months, respiratory rate ≥60 breaths per minute, arterial hemoglobin saturation ≤92 percent, and absence of vomiting [<a href="#rid11">11</a>]. A typical chest radiograph may show bilateral perihilar interstitial infiltrates that become more homogeneous and diffuse as the disease progresses  (<a class="graphic graphic_diagnosticimage graphicRef80631" href="/d/graphic/80631.html" rel="external">image 1</a>). When chest radiographic findings are normal, high-resolution computed tomography may reveal extensive ground-glass opacities, with a patchy distribution affecting the central lung, sparing the lung periphery [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/3704.html" rel="external">"Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV", section on 'Radiographic manifestations'</a>.)</p><p><em>P</em>. <em>jirovecii</em> cannot be cultured in the laboratory, and definitive diagnosis relies on microscopic demonstration of the organism in pulmonary fluids or tissues in the presence of clinical disease. Specific stains and fluorescently conjugated monoclonal antibody allow visualization of the cyst capsule of the organism. Pulmonary fluid or tissue may be obtained from bronchoalveolar lavage, induced sputum, intubation with deep endotracheal aspiration, or lung biopsy in settings where these procedures are available. In resource-limited settings, appropriate specimens have been obtained through sputum induction or nasogastric aspirates [<a href="#rid13">13</a>]. Polymerase chain reaction has been used to diagnose PCP in children and has been found to be more sensitive but less specific compared with microscopic methods [<a href="#rid14">14,15</a>]. Polymerase chain reaction has the advantage that testing can be performed on oral washes and nasopharyngeal aspirates; however, these tests are not standardized and are not available in many centers [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/3704.html" rel="external">"Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV", section on 'Evaluation and diagnosis'</a>.)</p><p>The mortality rate in immunocompromised patients ranges from 5 to 40 percent if treated and approaches 100 percent if untreated. Because one-half of all cases of PCP in children with perinatally acquired HIV occur in infants three to six months of age, early identification of HIV-exposed infants and timely initiation of prophylaxis is essential to prevent PCP-related deaths.</p><p>Chemoprophylaxis and treatment of PCP in individuals with HIV infection are discussed in a separate topic review. (See  <a class="medical medical_review" href="/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV"</a>.)</p><p class="headingAnchor" id="H18840526"><span class="h3">Recurrent bacterial infections</span><span class="headingEndMark"> — </span>Bacterial infections occur commonly in children with HIV infection. Before the era of combination ART, pneumonia and bacteremia were the two bacterial infections observed most commonly [<a href="#rid17">17</a>]. <em>Streptococcus</em> <em>pneumoniae</em>, <em>Salmonella</em> species, <em>Staphylococcus</em> <em>aureus</em>, and <em>Haemophilus</em> <em>influenzae</em> type b are the bacteria isolated most frequently. <em>Pseudomonas</em> is associated with late-stage disease and severe immunosuppression [<a href="#rid6">6</a>]. Risk factors for bacterial infection in children with HIV have not been defined precisely, but young children with vertically acquired HIV appear to be at particular risk [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H18840533"><span class="h3">Wasting syndrome</span><span class="headingEndMark"> — </span>Wasting refers to loss of lean body mass and is defined by meeting at least one of the following criteria in the absence of a concurrent illness other than HIV:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent weight loss greater than 10 percent of baseline</p><p class="bulletIndent1"><span class="glyph">●</span>Downward crossing of two or more major percentile lines on the pediatric weight-for-age chart (eg, 95<sup>th</sup>, 75<sup>th</sup>, 50<sup>th</sup>, 25<sup>th</sup>, 5<sup>th</sup>)</p><p class="bulletIndent1"><span class="glyph">●</span>Less than 5<sup>th</sup> percentile on weight-for-height chart on two consecutive measurements 30 or more days apart, plus chronic diarrhea or documented fever</p><p></p><p>Wasting is a well-recognized AIDS-defining condition for children and adults. HIV infection per se, OI, and increased metabolic demands all can lead to loss of weight and lean body mass. In children, wasting can severely impact normal growth and development. Wasting also is associated with a high risk for HIV disease progression and short-term mortality [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H18840540"><span class="h3">Esophageal candidiasis</span><span class="headingEndMark"> — </span>Clinical features and risk factors for the development of esophageal candidiasis have not been widely addressed in children with HIV. In a retrospective study of 448 children with HIV followed at the National Cancer Institute between 1987 and 1995 (prior to use of combination ART), 8 percent had at least one episode of esophageal candidiasis and several children had multiple episodes [<a href="#rid21">21</a>].</p><p>Risk factors for esophageal candidiasis included [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior oral candidiasis (present in nearly all affected children)</p><p class="bulletIndent1"><span class="glyph">●</span>Low CD4 count (which was an independent predictor)</p><p class="bulletIndent1"><span class="glyph">●</span>Receipt of antibiotics</p><p></p><p>Clinical manifestations included [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral thrush (94 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Odynophagia (80 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Retrosternal pain (57 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Fever (29 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea and/or vomiting (24 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Drooling or dehydration (12 percent each)</p><p class="bulletIndent1"><span class="glyph">●</span>Hoarseness (6 percent) </p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal bleeding (6 percent)</p><p></p><p>Evaluation and treatment of suspected esophageal candidiasis are discussed separately. (See  <a class="medical medical_review" href="/d/html/5972.html" rel="external">"Candida infections in children", section on 'Esophagitis'</a> and  <a class="medical medical_review" href="/d/html/3726.html" rel="external">"Evaluation of the patient with HIV, odynophagia, and dysphagia"</a>.)</p><p class="headingAnchor" id="H18840547"><span class="h3">HIV encephalopathy</span><span class="headingEndMark"> — </span>Neurodevelopmental and neurocognitive disorders are well-recognized complications of HIV infection. Most children with untreated HIV infection have central nervous system (CNS) abnormalities. (See  <a class="medical medical_review" href="/d/html/3723.html" rel="external">"HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – HIV encephalopathy is defined by one or more of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Failure to attain developmental milestones, loss of milestones, or loss of cognitive ability</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Impaired brain growth or acquired microcephaly, as determined by head circumference measurements, or brain atrophy demonstrated by computed tomography or magnetic resonance imaging</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acquired symmetric motor deficits manifested by two or more of the following: paresis, pathologic reflexes, ataxia, or gait disturbances</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated findings</strong> – HIV encephalopathy may be associated with spastic weakness of the extremities, microcephaly, seizures, and abnormalities on brain imaging (particularly cerebral atrophy and basal ganglia calcification  (<a class="graphic graphic_diagnosticimage graphicRef61731" href="/d/graphic/61731.html" rel="external">image 2</a>)). The encephalopathy may be static or progressive. Static HIV encephalopathy is more common and involves global cognitive and motor deficits with a normal rate of learning [<a href="#rid22">22</a>]. Progressive HIV encephalopathy, the most severe form of HIV encephalopathy, occurs almost exclusively in untreated HIV and involves severe developmental delay or regression of developmental milestones.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Manifestations of HIV encephalopathy may be due to the direct effects of HIV infection in the CNS, effects of immune mediators, or other unidentified agents. CNS infection by HIV generally is restricted to monocytes, macrophages, and their derivatives. Activation of these cells by HIV results in overproduction of inflammatory mediators. These inflammatory mediators and/or HIV viral proteins may serve as neurotoxins, eventually causing neuronal dysfunction and death. Inflammatory lesions, reactive gliosis, and white-matter degenerative changes are some of the neuropathologic findings noted in the brains of children with HIV [<a href="#rid23">23-25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – HIV encephalopathy is associated with the severity of clinical disease and is a common AIDS-defining condition in both high-income and low/middle-income countries, particularly in the era before widespread use of combination ART or in settings where access to ART is limited [<a href="#rid26">26-29</a>].</p><p></p><p class="bulletIndent1">Risk factors for the development of HIV encephalopathy include [<a href="#rid30">30-32</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lack of access to ART</p><p class="bulletIndent2"><span class="glyph">•</span>Advanced HIV disease</p><p class="bulletIndent2"><span class="glyph">•</span>Low CD4 count</p><p class="bulletIndent2"><span class="glyph">•</span>High viral load</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of ART</strong> – The use of highly active combination ART has greatly reduced the incidence of severe neurocognitive impairment in children. In addition, combination ART is effective in treating children with HIV encephalopathy and improves cognitive functioning, particularly when started early in the course of their disease or at a young age [<a href="#rid26">26,27,33-35</a>]. In a large prospective cohort study in the United States, there was a 50 percent reduction in the incidence of HIV encephalopathy after introduction of combination ART regimens [<a href="#rid36">36</a>]. However, HIV-related neurocognitive deficits can occur even in children on suppressive combination ART [<a href="#rid37">37-41</a>].</p><p></p><p class="bulletIndent1">The age and timing of ART initiation are important determinants in the development of HIV encephalopathy. The greatest risk for developing HIV encephalopathy is in the first 12 months of life; more than one-half of children who develop HIV encephalopathy are symptomatic by one year of age [<a href="#rid31">31</a>]. Compared with older children, young children with HIV have more severe delay in mental and motor development [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">In a randomized controlled trial evaluating the effects of early (before three months of age) or deferred (until clinical or immunologic progression) ART in 90 infants with HIV, the early treatment group had better neurodevelopmental functioning at median age of 11 months compared with infants with HIV whose treatment was deferred [<a href="#rid42">42</a>]. The fact that differences in infant neurodevelopmental functioning can be detected as early as one year of age based on ART treatment suggests that HIV damages the CNS very early in the course of infection and may explain in part why results of studies of children with HIV initiating combination ART later in childhood less definitively demonstrate improvement in neurocognitive function after effective ART treatment [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">Patients who attain cerebrospinal fluid (CSF) virologic suppression with combination ART therapy have greater improvement in neurocognitive functioning than those who do not [<a href="#rid43">43</a>]. Antiretroviral medications variably cross the blood-brain barrier, and, in some patients, there may be discordance between CSF and plasma HIV replication and potential for the development of CSF HIV resistance [<a href="#rid44">44,45</a>]. ART regimens including drugs with greater CNS penetration reduce virus load in CSF better compared with regimens with poorer CNS penetration but have not been definitively shown to improve cognitive performance [<a href="#rid36">36,43,46,47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – HIV encephalopathy is associated with increased mortality. Among infants enrolled in the Women and Infants Transmission Study, mortality of children diagnosed with HIV encephalopathy far exceeded that of the entire cohort (41 versus 12.5 percent) [<a href="#rid31">31</a>]. The median survival time after diagnosis of HIV encephalopathy was 22 months, similar to survival after diagnosis of PCP [<a href="#rid30">30</a>]. However, it is important to note that this study was carried out before the widespread use of combination ART, which, as described above, has dramatically reduced the incidence of HIV encephalopathy in the United States.</p><p></p><p class="headingAnchor" id="H18840554"><span class="h3">Cytomegalovirus disease</span><span class="headingEndMark"> — </span>CMV is ubiquitous and is transmitted from mother to child (during pregnancy, perinatally, and via breastfeeding) and by direct person-to-person contact with virus-containing secretions. In immunocompetent children, most infections are asymptomatic. An infectious mononucleosis-like syndrome with prolonged fever and mild hepatitis can occur. In patients with HIV/AIDS, CMV can present with fever, pneumonia, colitis, encephalitis, or retinitis. Early CMV infection may accelerate HIV disease progression in infants [<a href="#rid48">48</a>]. CMV infection in older children with perinatally acquired HIV infection appears to be associated with growth stunting and chronic lung disease [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/5965.html" rel="external">"Overview of cytomegalovirus infections in children", section on 'Immunocompromised hosts'</a>.)</p><p>CMV retinitis  (<a class="graphic graphic_picture graphicRef60074" href="/d/graphic/60074.html" rel="external">picture 1</a>) is rare in the combination ART era and occurs principally among children with HIV and severe immunosuppression. CMV retinitis can lead to blindness if untreated, and, therefore, patients should be advised to report to the clinic if they notice changes in their vision, including blurry vision or "floaters." However, many patients are completely asymptomatic and regular funduscopic examinations are necessary to detect changes. Patients with funduscopic changes should be referred to an ophthalmologist, as indicated. (See  <a class="medical medical_review" href="/d/html/3746.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/3731.html" rel="external">"Treatment of AIDS-related cytomegalovirus retinitis"</a>.)</p><p class="headingAnchor" id="H18840561"><span class="h3">Other</span><span class="headingEndMark"> — </span>A wide variety of other clinical manifestations of pediatric HIV infection have been described.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other AIDS-defining conditions</strong> – Other AIDS-defining conditions include  (<a class="graphic graphic_table graphicRef59724" href="/d/graphic/59724.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary candidiasis</p><p class="bulletIndent2"><span class="glyph">•</span>Cryptosporidiosis</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic herpes simplex virus</p><p class="bulletIndent2"><span class="glyph">•</span>Kaposi sarcoma</p><p class="bulletIndent2"><span class="glyph">•</span><em>Mycobacterium</em> <em>avium</em> complex infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphoid interstitial pneumonia (LIP)</strong> – LIP is a form of interstitial lung disease that may be seen in patients with HIV  (<a class="graphic graphic_diagnosticimage graphicRef89082" href="/d/graphic/89082.html" rel="external">image 3</a>). It is characterized histopathologically by infiltration of the interstitium and alveolar spaces of the lung by lymphocytes, plasma cells, and other lymphoreticular elements. LIP is far more common in children than in adults; however, in the era of combination ART, the incidence of LIP has declined in both populations. (See  <a class="medical medical_review" href="/d/html/4361.html" rel="external">"Lymphoid interstitial pneumonia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic abnormalities</strong> – Anemia, thrombocytopenia, and leukopenia are frequently observed in children with HIV [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatologic manifestations</strong> – Common dermatologic manifestations include fungal, bacterial, and viral infections of the skin; severe seborrheic dermatitis; vasculitis; and drug eruptions. Oral findings include infections such as oral candidiasis, aphthous ulcers, and parotid gland swelling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal disease</strong> – Renal disease, with proteinuria, nephrotic syndrome, and renal insufficiency, has been reported [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac manifestations</strong> – Cardiomyopathy, pericardial effusion, myocarditis, and arrhythmia have been described in children with HIV, particularly those who are not receiving ART [<a href="#rid51">51,52</a>]. In one study, infants with HIV had higher heart rates and lower left ventricular fractional shortening compared with infants without HIV [<a href="#rid51">51</a>]. In another study of 68 children with AIDS, 28 percent of patients had serious cardiac events following progression to AIDS [<a href="#rid52">52</a>].</p><p></p><p class="headingAnchor" id="H18840568"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Outcomes of pediatric HIV infection depend upon whether effective treatment is provided.</p><p class="headingAnchor" id="H18840575"><span class="h2">Untreated HIV infection</span><span class="headingEndMark"> — </span>Without treatment, HIV infection causes progressive immunosuppression due to HIV virus-mediated depletion of CD4+ lymphocytes, leaving patients at risk of developing opportunistic infections (OIs) and other HIV-related disorders. </p><p>Infants and young children with HIV have a particularly high risk for disease progression with up to 50 percent of children born with HIV dying before 2 years of age without treatment [<a href="#rid53">53,54</a>]. By five years of age the risk of disease progress and mortality in the absence of treatment is similar to those observed among young adults [<a href="#rid55">55</a>]. </p><p>The timing of HIV transmission from mother to child seems to be an important determinant of disease progression. Children infected in utero or within the first one to two months of life have a higher mortality rate at 12 months than those infected later [<a href="#rid54">54,56</a>]. Among a small South African cohort of infants with HIV infection born to mothers who received antiretroviral medications to prevent mother-to-child transmission of HIV, 35, 70, and 80 percent of infants progressed to severe immunosuppression within 3, 6, and 12 months of life, respectively. Rapid progression was inversely related to maternal CD4 count and more common in infants with intrauterine infection [<a href="#rid57">57</a>]. Other factors, including early onset of HIV-related conditions, failure to thrive, and generalized lymphadenopathy, were all poor prognostic features, whereas lymphoid interstitial pneumonia (LIP) was associated with milder illness [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H18840582"><span class="h2">HIV infection treated with antiretroviral therapy</span><span class="headingEndMark"> — </span>Antiretroviral treatment has been shown to have unequivocal benefits for immune function, growth and developmental outcomes in children with HIV [<a href="#rid58">58-60</a>], leading the WHO [<a href="#rid61">61,62</a>] and the United States ART guidelines [<a href="#rid62">62</a>] to recommend the timely initiation of combination ART for all children with HIV infection regardless of age, CD4 count, or HIV viral load.</p><p>Among children and adolescents with HIV, increasing use of effective combination ART regimens has resulted in a steep decline in mortality [<a href="#rid63">63,64</a>]. Additional benefits of combination ART in children and adolescents with HIV include improved growth, improvement in immune function, and marked decrease in the incidence of OIs [<a href="#rid64">64-67</a>].</p><p class="headingAnchor" id="H565375"><span class="h3">Mortality</span></p><p class="headingAnchor" id="H566003"><span class="h4">Developed settings</span><span class="headingEndMark"> — </span>In the United States and other developed countries, the mortality rate among children with HIV in the era of highly effective combination ART is approximately 0.5 to 0.9 per 100 children per year [<a href="#rid68">68-74</a>].</p><p>In a study from the Pediatric AIDS Clinical Trials Group (PACTG), which included children with HIV enrolled between April 1993 and December 2006 and followed for a median of 5.3 years, the following observations characterize trends in HIV mortality in a developed setting [<a href="#rid68">68</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 3553 enrolled children, there were 298 deaths (1.47 deaths per 100 person-years).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Between 1994 and 2000, the mortality rate decreased from 7.2 to 0.8 deaths per 100 person-years; mortality rate was inversely associated with combination ART treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The six-year survival probability increased for each successive birth cohort (from 81 percent for those born before 1985 to 99 percent for those born during 2000 to 2006).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combination ART was associated with prolongation of life; among children who died, the mean age at death increased from 8.9 years in 1994 to 18.2 years in 2006.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for death included CD4 percent &lt;15, having an AIDS-defining condition  (<a class="graphic graphic_table graphicRef59724" href="/d/graphic/59724.html" rel="external">table 1</a>) at study entry, younger age at entry, and belonging to an early birth cohort.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ninety-seven percent of deaths were directly attributable to HIV infection. Between 1994 to 1996 and 2001 to 2006, the proportion of deaths caused by OI declined from 36 to 24 percent; the proportion of deaths due to <em>P</em>. <em>jirovecii</em> pneumonia (PCP) and cytomegalovirus (CMV) remained unchanged; and the proportion of deaths due to end-stage AIDS, sepsis, and renal failure increased.</p><p></p><p>In a subsequent study from the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) network including patients enrolled between 2009 to 2013 and followed for a median of 3.7 years, the mortality rate declined even further to approximately 0.6 per 100 patients per year [<a href="#rid74">74</a>]. Combination ART was used in 85 percent of patients (compared with 75 percent of patients in the PACTG study between 2004 and 2007). Most deaths (86 percent) were directly linked to infection or other HIV-associated medical conditions. The most common primary causes of death included pneumonia, advanced AIDS, progressive multifocal leukoencephalopathy, and sepsis.</p><p class="headingAnchor" id="H429436"><span class="h4">Resource-limited settings</span><span class="headingEndMark"> — </span>In resource-limited settings, several studies using pooled data from different cohorts have found similar improvements in the outcomes of children with HIV treated with combination ART [<a href="#rid60">60,75-78</a>]. However, delays in starting ART in resource-limited settings are likely a major reason for high mortality rates seen in some studies.</p><p>In the available studies, mortality rates at one, two, and three years were 4.5, 6.9, and 7.7 percent, respectively [<a href="#rid75">75-77</a>]. These rates are similar to those observed among children in developed settings. The effectiveness of ART in resource-limited settings has also been demonstrated in an analysis of data pooled from cohorts from 15 countries in Asia, Africa, and the Caribbean [<a href="#rid78">78</a>].</p><p>Despite these encouraging results and increasing access to ART, mortality remains high for children with HIV in low- and middle-income countries. Risk factors for mortality in the first year of ART treatment include young age, low CD4 percent, advanced clinical disease, anemia, and low weight for age [<a href="#rid75">75-77,79-81</a>].</p><p>Early diagnosis and treatment of infants with HIV dramatically decreases morbidity and mortality. The Children with HIV Early Antiretroviral Therapy (CHER) study demonstrated that in perinatally infected infants with normal immune function, initiating ART early (before 12 weeks of age) compared with delaying ART until the child met clinical or immune criteria reduced mortality by 75 percent [<a href="#rid82">82</a>]. Based in part on results from the CHER study, the World Health Organization (WHO) revised its treatment recommendations to include virologic testing of all infants with HIV at four to six weeks of age and treatment of all children with HIV less than 12 months of age, regardless of immunologic or clinical stage [<a href="#rid83">83</a>].</p><p>Early infant diagnosis and prompt initiation of ART remains a challenge in resource-limited settings, and delays in starting ART are likely a major reason for the high mortality rates seen in resource-limited settings. Treatment of young children in resource-limited settings lags behind that of older children and adults. In pooled analyses, the median age of children treated with ART ranged from 3.5 to 4.9 years [<a href="#rid75">75-77</a>]. Approximately 30 percent of children treated with ART are &lt;18 months of age, and only 12 to 24 percent of patients are &lt;12 months [<a href="#rid75">75-77</a>]. In a study using data from a large international cohort of children with HIV, approximately two-thirds of children in low- and middle-income countries already had severe immunodeficiency at the initiation of ART [<a href="#rid84">84</a>]. The small proportion of young children receiving ART and the failure to start ART prior to the onset of severe immunodeficiency highlights the continued need to scale up programs in resource-limited settings to improve the early identification of infants exposed to and infected with HIV and to assure appropriate follow-up and timely initiation of treatment.</p><p class="headingAnchor" id="H565934"><span class="h3">Long-term morbidities</span><span class="headingEndMark"> — </span>In children and young adults treated for HIV infection in childhood, common long-term morbidities include [<a href="#rid69">69,85-94</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mental health concerns, including anxiety, mood, and substance abuse disorders (25 to 60 percent) (see  <a class="medical medical_review" href="/d/html/1224.html" rel="external">"Pediatric unipolar depression: Epidemiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/15926.html" rel="external">"Anxiety disorders in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dyslipidemia (25 to 50 percent) (see  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular complications, including cardiomyopathy and accelerated atherosclerosis (10 to 20 percent) (see  <a class="medical medical_review" href="/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a> and  <a class="medical medical_review" href="/d/html/5753.html" rel="external">"Overview of the management of the child or adolescent at risk for atherosclerosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insulin resistance and diabetes mellitus (approximately 15 percent) (see  <a class="medical medical_review" href="/d/html/5820.html" rel="external">"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased bone mineral density (2 to 7 percent) (see  <a class="medical medical_review" href="/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/2036.html" rel="external">"Drugs that affect bone metabolism", section on 'Antiretroviral therapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal disease (2 to 7 percent) (see  <a class="medical medical_review" href="/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course"</a> and  <a class="medical medical_review" href="/d/html/6134.html" rel="external">"Chronic kidney disease in children: Clinical manifestations and evaluation"</a>)</p><p></p><p class="headingAnchor" id="H770285743"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113065.html" rel="external">"Society guideline links: HIV infection in adolescents"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112595.html" rel="external">"Society guideline links: HIV infection in infants and children"</a>.)</p><p class="headingAnchor" id="H11141365"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Case definitions – </strong>The Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have developed differing classification systems for pediatric HIV/acquired immunodeficiency syndrome (AIDS) to standardize the description of HIV infection cases for public health surveillance and research purposes  (<a class="graphic graphic_table graphicRef95236" href="/d/graphic/95236.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef95235" href="/d/graphic/95235.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef104882" href="/d/graphic/104882.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef57988" href="/d/graphic/57988.html" rel="external">table 5</a>). (See <a class="local">'Case definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations – </strong>The clinical manifestations of pediatric HIV infection are varied and often nonspecific (eg, lymphadenopathy, oral candidiasis, failure to thrive). The most common AIDS-defining conditions in children in the United States include <em>Pneumocystis</em> <em>jirovecii</em> pneumonia (PCP), recurrent bacterial infections, wasting syndrome, candida esophagitis, HIV encephalopathy, and cytomegalovirus (CMV)  (<a class="graphic graphic_table graphicRef59724" href="/d/graphic/59724.html" rel="external">table 1</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes – </strong>Outcomes of HIV infection depend upon whether effective treatment is provided. Highly effective, combination antiretroviral therapy (ART) has radically reduced mortality and morbidity, particularly the incidence of opportunistic infections (Ois). (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Untreated HIV infection - </strong>Without treatment, HIV infection causes progressive immunosuppression, leaving patients at risk of developing OI and other HIV-related disorders. Most untreated children with HIV die before age five years. However, there is considerable variability, particularly for those with vertically acquired infection. (See <a class="local">'Untreated HIV infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiretroviral therapy – </strong>Combination ART is associated with improvement in virologic, immunologic, and clinical health for adults and children with HIV. The use of combination ART in children has reduced the morbidity and mortality associated with HIV infection in the developed world. However, limited access to adequate health care to sustain widespread HIV diagnosis and treatment has hampered progress in controlling HIV in resource-limited settings. (See <a class="local">'HIV infection treated with antiretroviral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term morbidities – </strong>Long-term morbidities in children and young adults treated for HIV infection in childhood include mental health concerns, dyslipidemia, insulin resistance and diabetes mellitus, cardiovascular complications, decreased bone mineral density, and renal disease. (See <a class="local">'Long-term morbidities'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Luzuriaga K, Mofenson LM. Challenges in the Elimination of Pediatric HIV-1 Infection. N Engl J Med 2016; 374:761.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Revised surveillance case definition for HIV infection--United States, 2014. MMWR Recomm Rep 2014; 63:1.</a></li><li><a class="nounderline abstract_t">Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged &lt;18 months and for HIV infection and AIDS among children aged 18 months to &lt;13 years--United States, 2008. MMWR Recomm Rep 2008; 57:1.</a></li><li class="breakAll">World Health Organization.  WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children.  World Health Organization, Geneva, Switzerland, 2007, 1-48.</li><li class="breakAll">World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015. Available at: www.who.int/hiv/pub/guidelines/earlyrelease-arv/en.</li><li><a class="nounderline abstract_t">Dankner WM, Lindsey JC, Levin MJ, Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20:40.</a></li><li><a class="nounderline abstract_t">Nesheim SR, Kapogiannis BG, Soe MM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 2007; 120:100.</a></li><li><a class="nounderline abstract_t">Candiani TM, Pinto J, Cardoso CA, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publica 2007; 23 Suppl 3:S414.</a></li><li><a class="nounderline abstract_t">Kourtis AP, Bansil P, Posner SF, et al. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample. Pediatrics 2007; 120:e236.</a></li><li><a class="nounderline abstract_t">Simonds RJ, Oxtoby MJ, Caldwell MB, et al. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993; 270:470.</a></li><li><a class="nounderline abstract_t">Fatti GL, Zar HJ, Swingler GH. Clinical indicators of Pneumocystis jiroveci pneumonia (PCP) in South African children infected with the human immunodeficiency virus. Int J Infect Dis 2006; 10:282.</a></li><li><a class="nounderline abstract_t">Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007; 13:1.</a></li><li><a class="nounderline abstract_t">Surve TY, Rathod AD. Role of naso-gastric aspirate in HIV-positive children presenting with respiratory symptoms. J Trop Pediatr 2006; 52:451.</a></li><li><a class="nounderline abstract_t">Morrow BM, Samuel CM, Zampoli M, et al. Pneumocystis pneumonia in South African children diagnosed by molecular methods. BMC Res Notes 2014; 7:26.</a></li><li><a class="nounderline abstract_t">Samuel CM, Whitelaw A, Corcoran C, et al. Improved detection of Pneumocystis jirovecii in upper and lower respiratory tract specimens from children with suspected pneumocystis pneumonia using real-time PCR: a prospective study. BMC Infect Dis 2011; 11:329.</a></li><li><a class="nounderline abstract_t">Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58:1.</a></li><li><a class="nounderline abstract_t">Katkin JP, Hansen TN, Langston C, Hiatt PW. Pulmonary manifestations of AIDS in children. Semin Pediatr Infect Dis 1990; 1:40.</a></li><li><a class="nounderline abstract_t">Bernstein LJ, Krieger BZ, Novick B, et al. Bacterial infection in the acquired immunodeficiency syndrome of children. Pediatr Infect Dis 1985; 4:472.</a></li><li><a class="nounderline abstract_t">Krasinski K, Borkowsky W, Holzman RS. Prognosis of human immunodeficiency virus infection in children and adolescents. Pediatr Infect Dis J 1989; 8:216.</a></li><li><a class="nounderline abstract_t">Tovo PA, de Martino M, Gabiano C, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. Lancet 1992; 339:1249.</a></li><li><a class="nounderline abstract_t">Chiou CC, Groll AH, Gonzalez CE, et al. Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factors. Pediatr Infect Dis J 2000; 19:729.</a></li><li><a class="nounderline abstract_t">Tahan TT, Bruck I, Burger M, Cruz CR. Neurological profile and neurodevelopment of 88 children infected with HIV and 84 seroreverter children followed from 1995 to 2002. Braz J Infect Dis 2006; 10:322.</a></li><li><a class="nounderline abstract_t">Mintz M, Epstein LG, Koenigsberger MR. Neurological manifestations of acquired immunodeficiency syndrome in children. Int Pediatr 1989; 4:161.</a></li><li><a class="nounderline abstract_t">Michaels J, Sharer LR, Epstein LG. Human immunodeficiency virus type 1 (HIV-1) infection of the nervous system: a review. Immunodefic Rev 1988; 1:71.</a></li><li><a class="nounderline abstract_t">Sharer LR, Epstein LG, Cho ES, et al. Pathologic features of AIDS encephalopathy in children: evidence for LAV/HTLV-III infection of brain. Hum Pathol 1986; 17:271.</a></li><li><a class="nounderline abstract_t">Van Rie A, Mupuala A, Dow A. Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Democratic Republic of the Congo. Pediatrics 2008; 122:e123.</a></li><li><a class="nounderline abstract_t">Van Rie A, Dow A, Mupuala A, Stewart P. Neurodevelopmental trajectory of HIV-infected children accessing care in Kinshasa, Democratic Republic of Congo. J Acquir Immune Defic Syndr 2009; 52:636.</a></li><li><a class="nounderline abstract_t">Baillieu N, Potterton J. The extent of delay of language, motor, and cognitive development in HIV-positive infants. J Neurol Phys Ther 2008; 32:118.</a></li><li><a class="nounderline abstract_t">Nachman S, Chernoff M, Williams P, et al. Human immunodeficiency virus disease severity, psychiatric symptoms, and functional outcomes in perinatally infected youth. Arch Pediatr Adolesc Med 2012; 166:528.</a></li><li><a class="nounderline abstract_t">Lobato MN, Caldwell MB, Ng P, Oxtoby MJ. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Pediatric Spectrum of Disease Clinical Consortium. J Pediatr 1995; 126:710.</a></li><li><a class="nounderline abstract_t">Cooper ER, Hanson C, Diaz C, et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. Women and Infants Transmission Study Group. J Pediatr 1998; 132:808.</a></li><li><a class="nounderline abstract_t">Shanbhag MC, Rutstein RM, Zaoutis T, et al. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy. Arch Pediatr Adolesc Med 2005; 159:651.</a></li><li><a class="nounderline abstract_t">Lindsey JC, Malee KM, Brouwers P, et al. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics 2007; 119:e681.</a></li><li><a class="nounderline abstract_t">Smith R, Malee K, Leighty R, et al. Effects of perinatal HIV infection and associated risk factors on cognitive development among young children. Pediatrics 2006; 117:851.</a></li><li><a class="nounderline abstract_t">Benki-Nugent S, Wamalwa D, Langat A, et al. Comparison of developmental milestone attainment in early treated HIV-infected infants versus HIV-unexposed infants: a prospective cohort study. BMC Pediatr 2017; 17:24.</a></li><li><a class="nounderline abstract_t">Patel K, Ming X, Williams PL, et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009; 23:1893.</a></li><li><a class="nounderline abstract_t">Paramesparan Y, Garvey LJ, Ashby J, et al. High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. J Acquir Immune Defic Syndr 2010; 55:134.</a></li><li><a class="nounderline abstract_t">Crowell CS, Malee KM, Yogev R, Muller WJ. Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy. Rev Med Virol 2014; 24:316.</a></li><li><a class="nounderline abstract_t">Puthanakit T, Aurpibul L, Louthrenoo O, et al. Poor cognitive functioning of school-aged children in thailand with perinatally acquired HIV infection taking antiretroviral therapy. AIDS Patient Care STDS 2010; 24:141.</a></li><li><a class="nounderline abstract_t">Puthanakit T, Saphonn V, Ananworanich J, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis 2012; 12:933.</a></li><li><a class="nounderline abstract_t">Puthanakit T, Ananworanich J, Vonthanak S, et al. Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J 2013; 32:501.</a></li><li><a class="nounderline abstract_t">Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 2012; 26:1685.</a></li><li><a class="nounderline abstract_t">Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56:416.</a></li><li><a class="nounderline abstract_t">Eggers C, Hertogs K, Stürenburg HJ, et al. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003; 17:1897.</a></li><li><a class="nounderline abstract_t">Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773.</a></li><li><a class="nounderline abstract_t">Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359.</a></li><li><a class="nounderline abstract_t">Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009; 52:56.</a></li><li><a class="nounderline abstract_t">Ellington SR, Clarke KE, Kourtis AP. Cytomegalovirus Infection in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Infants: A Systematic Review. J Infect Dis 2016; 213:891.</a></li><li><a class="nounderline abstract_t">Yindom LM, Simms V, Majonga ED, et al. Unexpectedly High Prevalence of Cytomegalovirus DNAemia in Older Children and Adolescents With Perinatally Acquired Human Immunodeficiency Virus Infection. Clin Infect Dis 2019; 69:580.</a></li><li><a class="nounderline abstract_t">Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998; 91:1479.</a></li><li><a class="nounderline abstract_t">Lipshultz SE, Easley KA, Orav EJ, et al. Cardiovascular status of infants and children of women infected with HIV-1 (P(2)C(2) HIV): a cohort study. Lancet 2002; 360:368.</a></li><li><a class="nounderline abstract_t">Al-Attar I, Orav EJ, Exil V, et al. Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J Am Coll Cardiol 2003; 41:1598.</a></li><li><a class="nounderline abstract_t">Spira R, Lepage P, Msellati P, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics 1999; 104:e56.</a></li><li><a class="nounderline abstract_t">Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236.</a></li><li><a class="nounderline abstract_t">Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197:398.</a></li><li><a class="nounderline abstract_t">Mbori-Ngacha D, Nduati R, John G, et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial. JAMA 2001; 286:2413.</a></li><li><a class="nounderline abstract_t">Mphatswe W, Blanckenberg N, Tudor-Williams G, et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS 2007; 21:1253.</a></li><li><a class="nounderline abstract_t">Chiappini E, Galli L, Tovo PA, et al. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC Infect Dis 2009; 9:140.</a></li><li><a class="nounderline abstract_t">Guillén S, García San Miguel L, Resino S, et al. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006). HIV Med 2010; 11:245.</a></li><li><a class="nounderline abstract_t">Le Doaré K, Bland R, Newell ML. Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics 2012; 130:e1326.</a></li><li class="breakAll">World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. March 2021. https://www.who.int/publications/i/item/9789240022232 (Accessed on November 14, 2023).</li><li class="breakAll">Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Department of Health and Human Services, 2023. Available at https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv (Accessed on September 25, 2023).</li><li><a class="nounderline abstract_t">de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000; 284:190.</a></li><li><a class="nounderline abstract_t">Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345:1522.</a></li><li><a class="nounderline abstract_t">Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006; 296:292.</a></li><li><a class="nounderline abstract_t">Sauvageot D, Schaefer M, Olson D, et al. Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children &lt;5 years of age. Pediatrics 2010; 125:e1039.</a></li><li><a class="nounderline abstract_t">Peacock-Villada E, Richardson BA, John-Stewart GC. Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. Pediatrics 2011; 127:e423.</a></li><li><a class="nounderline abstract_t">Brady MT, Oleske JM, Williams PL, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010; 53:86.</a></li><li><a class="nounderline abstract_t">Berti E, Thorne C, Noguera-Julian A, et al. The new face of the pediatric HIV epidemic in Western countries: demographic characteristics, morbidity and mortality of the pediatric HIV-infected population. Pediatr Infect Dis J 2015; 34:S7.</a></li><li><a class="nounderline abstract_t">Chiappini E, Galli L, Tovo PA, et al. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS 2007; 21:1607.</a></li><li><a class="nounderline abstract_t">Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918.</a></li><li><a class="nounderline abstract_t">Palladino C, Climent FJ, José MI, et al. Causes of death in pediatric patients vertically infected by the human immunodeficiency virus type 1 in Madrid, Spain, from 1982 to mid-2009. Pediatr Infect Dis J 2011; 30:495.</a></li><li><a class="nounderline abstract_t">Kapogiannis BG, Soe MM, Nesheim SR, et al. Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Clin Infect Dis 2011; 53:1024.</a></li><li><a class="nounderline abstract_t">Mirani G, Williams PL, Chernoff M, et al. Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy. Clin Infect Dis 2015; 61:1850.</a></li><li><a class="nounderline abstract_t">Fenner L, Brinkhof MW, Keiser O, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr 2010; 54:524.</a></li><li><a class="nounderline abstract_t">KIDS-ART-LINC Collaboration. Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2008; 49:523.</a></li><li><a class="nounderline abstract_t">Davies MA, Keiser O, Technau K, et al. Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J 2009; 99:730.</a></li><li><a class="nounderline abstract_t">Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis 2009; 49:1915.</a></li><li><a class="nounderline abstract_t">Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298:1888.</a></li><li><a class="nounderline abstract_t">Walker AS, Prendergast AJ, Mugyenyi P, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis 2012; 55:1707.</a></li><li><a class="nounderline abstract_t">Davies MA, May M, Bolton-Moore C, et al. Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programs. Pediatr Infect Dis J 2014; 33:608.</a></li><li><a class="nounderline abstract_t">Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233.</a></li><li class="breakAll">World Health Organization.  Antiretroviral therapy of HIV infection in infants and children: towards universal access: Recommendation for a public health approach. World Health Organization, Geneva, Switzerland, 2010, 1- 206.</li><li><a class="nounderline abstract_t">Koller M, Patel K, Chi BH, et al. Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2015; 68:62.</a></li><li><a class="nounderline abstract_t">Fortuny C, Deyà-Martínez Á, Chiappini E, et al. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. Pediatr Infect Dis J 2015; 34:S36.</a></li><li><a class="nounderline abstract_t">Shahinian V, Rajaraman S, Borucki M, et al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000; 35:884.</a></li><li><a class="nounderline abstract_t">Papi L, Menezes AC, Rocha H, et al. Prevalence of lipodystrophy and risk factors for dyslipidemia in HIV-infected children in Brazil. Braz J Infect Dis 2014; 18:394.</a></li><li><a class="nounderline abstract_t">Miller TI, Borkowsky W, DiMeglio LA, et al. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med 2012; 13:264.</a></li><li><a class="nounderline abstract_t">Lipshultz SE, Williams PL, Wilkinson JD, et al. Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study. JAMA Pediatr 2013; 167:520.</a></li><li><a class="nounderline abstract_t">Lipshultz SE, Miller TL, Wilkinson JD, et al. Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America. J Int AIDS Soc 2013; 16:18597.</a></li><li><a class="nounderline abstract_t">DiMeglio LA, Wang J, Siberry GK, et al. Bone mineral density in children and adolescents with perinatal HIV infection. AIDS 2013; 27:211.</a></li><li><a class="nounderline abstract_t">Chernoff M, Nachman S, Williams P, et al. Mental health treatment patterns in perinatally HIV-infected youth and controls. Pediatrics 2009; 124:627.</a></li><li><a class="nounderline abstract_t">Gadow KD, Angelidou K, Chernoff M, et al. Longitudinal study of emerging mental health concerns in youth perinatally infected with HIV and peer comparisons. J Dev Behav Pediatr 2012; 33:456.</a></li><li><a class="nounderline abstract_t">Mellins CA, Elkington KS, Leu CS, et al. Prevalence and change in psychiatric disorders among perinatally HIV-infected and HIV-exposed youth. AIDS Care 2012; 24:953.</a></li></ol></div><div id="topicVersionRevision">Topic 5963 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26933850" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Challenges in the Elimination of Pediatric HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24717910" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Revised surveillance case definition for HIV infection--United States, 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052530" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged&lt;18 months and for HIV infection and AIDS among children aged 18 months to&lt;13 years--United States, 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052530" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged&lt;18 months and for HIV infection and AIDS among children aged 18 months to&lt;13 years--United States, 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052530" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged&lt;18 months and for HIV infection and AIDS among children aged 18 months to&lt;13 years--United States, 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176565" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606567" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17992347" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606535" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320786" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16460981" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical indicators of Pneumocystis jiroveci pneumonia (PCP) in South African children infected with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17334722" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16870685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Role of naso-gastric aspirate in HIV-positive children presenting with respiratory symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24410938" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pneumocystis pneumonia in South African children diagnosed by molecular methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123076" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Improved detection of Pneumocystis jirovecii in upper and lower respiratory tract specimens from children with suspected pneumocystis pneumonia using real-time PCR: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19730409" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary manifestations of AIDS in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3900944" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bacterial infection in the acquired immunodeficiency syndrome of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2717274" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prognosis of human immunodeficiency virus infection in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1349667" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10959741" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17293919" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neurological profile and neurodevelopment of 88 children infected with HIV and 84 seroreverter children followed from 1995 to 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Neurological manifestations of acquired immunodeficiency syndrome in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3078711" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Human immunodeficiency virus type 1 (HIV-1) infection of the nervous system: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3005158" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pathologic features of AIDS encephalopathy in children: evidence for LAV/HTLV-III infection of brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18595957" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Democratic Republic of the Congo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19730268" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neurodevelopmental trajectory of HIV-infected children accessing care in Kinshasa, Democratic Republic of Congo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978667" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The extent of delay of language, motor, and cognitive development in HIV-positive infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22312169" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Human immunodeficiency virus disease severity, psychiatric symptoms, and functional outcomes in perinatally infected youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751993" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Pediatric Spectrum of Disease Clinical Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9602190" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. Women and Infants Transmission Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996999" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296781" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510667" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effects of perinatal HIV infection and associated risk factors on cognitive development among young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28095807" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparison of developmental milestone attainment in early treated HIV-infected infants versus HIV-unexposed infants: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644348" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733406" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24806816" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20214481" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Poor cognitive functioning of school-aged children in thailand with perinatally acquired HIV infection taking antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23059199" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23263176" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22614886" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Early antiretroviral therapy improves neurodevelopmental outcomes in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15349869" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12960822" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100092" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19424052" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19731418" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26597258" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cytomegalovirus Infection in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Infants: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30828710" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Unexpectedly High Prevalence of Cytomegalovirus DNAemia in Older Children and Adolescents With Perinatally Acquired Human Immunodeficiency Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9473211" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The influence of human immunodeficiency virus-1 on hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241776" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cardiovascular status of infants and children of women infected with HIV-1 (P(2)C(2) HIV): a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742303" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10545582" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15464184" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18248303" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11712936" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17545701" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19709432" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20050937" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118140" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Neurodevelopment in children born to HIV-infected mothers by infection and treatment status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118140" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Neurodevelopment in children born to HIV-infected mothers by infection and treatment status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118140" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Neurodevelopment in children born to HIV-infected mothers by infection and treatment status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10889592" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794218" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849662" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Incidence of opportunistic and other infections in HIV-infected children in the HAART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385636" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children&lt;5 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21262891" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20035164" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25894975" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The new face of the pediatric HIV epidemic in Western countries: demographic characteristics, morbidity and mortality of the pediatric HIV-infected population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17630556" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17806062" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21326134" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Causes of death in pediatric patients vertically infected by the human immunodeficiency virus type 1 in Madrid, Spain, from 1982 to mid-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22002982" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26270680" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20588185" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18989227" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20128272" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19916798" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954540" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972859" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24378936" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020325" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Early antiretroviral therapy and mortality among HIV-infected infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020325" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Early antiretroviral therapy and mortality among HIV-infected infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25501345" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25629891" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10793023" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24794884" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prevalence of lipodystrophy and risk factors for dyslipidemia in HIV-infected children in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22136114" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23608879" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782480" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032412" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Bone mineral density in children and adolescents with perinatal HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19596734" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Mental health treatment patterns in perinatally HIV-infected youth and controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22772819" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Longitudinal study of emerging mental health concerns in youth perinatally infected with HIV and peer comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22519762" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Prevalence and change in psychiatric disorders among perinatally HIV-infected and HIV-exposed youth.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
